Acquisition adds new frataxin‑targeted modalities

Phase 2 data show strong safety and immunogenicity

Half of patients remained progression-free without maintenance

Partnership brings key medicines to eight markets

Company prepares seamless transition into phase 2a development

Nations commit US$240 million to CEPI’s 2027–2031 strategy

Grants support studies into restorative sleep and disease mechanisms

New option for patients with systemic lupus erythematosus

Deal strengthens company’s established medicines strategy

New format simplifies administration for clinicians